Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 636514, 5 pages
http://dx.doi.org/10.1155/2014/636514
Review Article

MMSET: Role and Therapeutic Opportunities in Multiple Myeloma

1Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, Singapore 117599
2Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, Singapore 119228
3Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore 119228

Received 17 March 2014; Accepted 16 June 2014; Published 1 July 2014

Academic Editor: Dong Soon Lee

Copyright © 2014 Zhigang Xie and Wee Joo Chng. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Recurrent chromosomal translocations are central to the pathogenesis, diagnosis, and prognosis of hematologic malignancies. The translocation t(4; 14)(p16; q32) is one of the most common translocations in multiple myeloma (MM) and is associated with very poor prognosis. The t(4; 14) translocation leads to the simultaneous overexpression of two genes, FGFR3 (fibroblast growth factor receptor 3) and MMSET (multiple myeloma SET domain), both of which have potential oncogenic activity. However, approximately 30% of t(4; 14) MM patients do not express FGFR3 and have poor prognosis irrespective of FGFR3 expression, whereas MMSET overexpression is universal in t(4; 14) cases. In this review, we provide an overview of recent findings regarding the oncogenic roles of MMSET in MM and its functions on histone methylation. We also highlight some of MMSET partners and its downstream signalling pathways and discuss the potential therapeutics targeting MMSET.